<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: A patient with an implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) may suffer from <z:e sem="disease" ids="C0852419,C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disorders</z:e> and may need to undergo a nerve conduction study (<z:chebi fb="7" ids="53203">NCS</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, a <z:chebi fb="7" ids="53203">NCS</z:chebi> may be a source of electromagnetic interference (EMI) </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to investigate whether the interference from <z:chebi fb="7" ids="53203">NCS</z:chebi> used in a standardised test protocol affects <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> function </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Twenty patients (19 males; mean age of 59.8Â±9.9 years) with implantable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> (eight with integrated and 12 with true bipolar leads), treated with <z:chebi fb="0" ids="2663">amiodarone</z:chebi> and with symptoms suggesting <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were included </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="7" ids="53203">NCS</z:chebi> were conducted using repetitive stimulation with frequency of 2 Hz and single, rectangular pulses of intensity up to 100 mA </plain></SENT>
<SENT sid="5" pm="."><plain>Stimulation was performed in standard sites including proximal sites in the arm </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The impulses generated <z:chebi fb="7" ids="53203">NCS</z:chebi> were not detected by the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>, irrespective of the site, rate or stimulus intensity </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Standardised test protocol for an <z:chebi fb="7" ids="53203">NCS</z:chebi> is safe in patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> regardless of the leads type </plain></SENT>
<SENT sid="8" pm="."><plain>SIGNIFICANCE: Current guidelines which limitate the <z:chebi fb="7" ids="53203">NCS</z:chebi> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> may be the subject of revision </plain></SENT>
</text></document>